A PYMNTS Company

US: Drug makers make $3.25B deal for multiple sclerosis drug

By  |  February 6, 2013

In what is still subject to a federal antitrust review, the boards of directors for two drug manufacturers have agreed to transfer full rights to the production of multiple sclerosis drug Tysabri. Elan and Biogen Idec have restructured their 50-50 split of the profits of the drug in a deal that gives Biogen full rights to it, while Elan gets a $3.25 billion payment and 12 percent of Biogen’s royalties of the drug for the first 12 months of the new agreement.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

     

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Full Content: Motley Fool

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.